Diabetes mellitus as a cause of end-stage renal disease in Europe: Signs of improvement

Clinical Kidney Journal

Volumn 9, Issue 3, 2016, Pages 454-456

  Van Den Brand, Jan A J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; END STAGE RENAL DISEASE; EUROPE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; NOTE; OBESITY; PRIORITY JOURNAL; SHORT TERM SURVIVAL;

EID: 84978958188     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw029     Document Type: Note

References (17)

1. Kramer A, Pippias M, Stel V et al. Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin Kidney J 2016; 9: 457-469
2. Guariguata L, Whiting DR, Hambleton I et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137-149
3. IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract 2013; 100: 277-279
4. Fox CS, Matsushita K,Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a metaanalysis. Lancet 2012; 380: 1662-1673
5. ShawJE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14
6. Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2. 7 million participants. Lancet 2011; 378: 31-40
7. Whiting DR, Guariguata L,Weil C et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321
8. van de LuijtgaardenMW, Noordzij M, van BiesenWet al. Conservative care in Europe-nephrologists' experience with the decision not to start renal replacement therapy. Nephrol Dial Transplant 2013; 28: 2604-2612
9. Caskey FJ, Kramer A, Elliott RF et al. Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 2011; 26: 2604-2610
10. Grams ME, Chow EK, Segev DL et al. Lifetime incidence of CKD stages 3-5 in the United States. AmJ Kidney Dis 2013; 62: 245-252
11. World Health Organization. Global Health Observatory-Blood Pressure. http://www. who. int/gho/ncd/risk-factors/blood- pressure-prevalence/en/
12. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21: 406-412
13. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800
14. JeffersonJA,ShanklandSJ,PichlerRH. Proteinuriaindiabetickidney disease: a mechanistic viewpoint. Kidney Int 2008; 74: 22-36
15. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562
16. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38
17. Centers for Disease Control and Prevention. Crude and Age-Adjusted Rates of Diagnosed Diabetes per 100 Civilian, Non-Institutionalized Adult Population, United States, 1980-2014. http://www. cdc. gov/diabetes/statistics/prev/national/figageadult. htm